MaaT Pharma and Skyepharma Complete Construction

• Major milestone achieved with new state-of-the-art microbiome facility spanning over 17,200 sq ft, completed within the 12-month timeframe, further enhancing bioproduction capabilities and contributing to the ecosystem in France and Europe
• MaaT Pharma is Skyepharma’s Skyehub Bioproduction® first resident company
• The facility was designed with the intent to support MaaT Pharma’s clinical-and commercial-scale manufacturing of Microbiome Ecosystem Therapies

Read the press release